Aktie A226950 OLIX PHARMACEUTICALS, INC
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen OliX Pharmaceuticals, Inc

Aktien

A226950

KR7226950004

A226950

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 30.04.2024 		% 5 Tage % 1. Jan.
15 670 KRW +1,10 % Intraday Chart für OliX Pharmaceuticals, Inc +2,82 % +7,48 %
2023 OliX Pharmaceuticals, Inc. erhält HREC-Genehmigung für den Beginn einer klinischen Phase-1-Studie mit einem Medikament gegen NASH und Fettleibigkeit CI
2023 OliX Pharmaceuticals gibt positive Sicherheitsdaten und vorläufige Wirksamkeitseffekte in einer Phase-1-Studie mit OLX10212 zur Behandlung der altersbedingten Makuladegeneration bekannt CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
OliX Pharmaceuticals, Inc announced that it has received KRW 14.7 billion in funding from a group of investors
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 14.7 billion in funding from a group of investors
OliX Pharmaceuticals, Inc Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH and Obesity Drug
OliX Pharmaceuticals, Inc announced that it has received KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.
OliX Pharmaceuticals, Inc announced that it expects to receive KRW 23.6 billion in funding from Kiwoom Investment Co., Ltd., AJU IB INVESTMENT Co., Ltd.
OliX Pharmaceuticals Announces Positive Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces First Patient in Phase 1 Clinical Study of RNAi Therapeutic OLX72021 for Androgenic Alopecia
OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2023
OliX Pharmaceuticals, Inc. Presents Preclinical Data Showing Synergistic Weight Loss from Anti-NASH siRNA and Semaglutide Combination Treatment
OliX Pharmaceuticals, Inc Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy Using RNA At Korea-US Digital BioHealth Business Forum
OliX Pharmaceuticals, Inc Announces Positive Results from A Phase 2A Trial of Olx10010 for Hypertrophic Scar Treatment
Olix Pharmaceuticals, Inc. Doses First Patient in Clinical Trial for Rnai Therapeutic Olx10212 for Dry and Wet Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Receives Regulatory Approval to Commence Phase 1 Clinical Trial of Treatment of Androgenic Alopecia
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd.
OliX Pharmaceuticals Publishes Preclinical Research Demonstrating OLX104C's Potential as an Effective Treatment for Hair Loss
Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential as an Effective Treatment for Hair Loss
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion.
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion.
OliX Pharmaceuticals, Inc Receives IND Approval from FDA to Develop RNAi Therapeutic OLX10212 for Age-Related Macular Degeneration
OliX Pharmaceuticals, Inc. Announces IND Submission to U.S. FDA to Evaluate Safety and Tolerability of OLX10212 in Phase 1 Clinical Trial
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A226950 Aktie
  4. Nachrichten OliX Pharmaceuticals, Inc
  5. Andere Sprachen